Rebecca Frey was named Chief Executive Officer of Yarrow Bioscience, Inc., succeeding David Domzalski. As of November 6, 2026, Yarrow Bioscience, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 28, 2026, naming 1 appointment and 1 departure (Form 8-K, July 28, 2026).
Who owns Yarrow Bioscience, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Yarrow Bioscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Yarrow Bioscience, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-28. It names 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Yarrow Bioscience, Inc. files it.
Also on the record for Yarrow Bioscience, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G, by Bellevue Group AG | 10.6% of the class | 5%+ stakes | Source |
| September 17, 2026 | Stake report, Schedule 13G, by Raymond Debbane | 7.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 8.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by venBio Global Strategic Fund V, L.P. | 9.99% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Zhang Xiaofan | 0.6% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP Ltd. | 9.99% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by Logos Global Management LP | 10.7% of the class | 5%+ stakes | Source |
| August 5, 2026 | Stake report, Schedule 13D, by ORBIMED ADVISORS LLC | 9.97% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G, by Logos Global Management LP | 9.9% of the class | 5%+ stakes | Source |
| August 3, 2026 | Stake report, Schedule 13G, by Perceptive Advisors LLC | 9.99% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by RTW Fund Group GP, LLC | 9.99% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13D/A, by AI Biotechnology LLC | 6.02% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Yarrow Bioscience, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Yarrow Bioscience, Inc. and the records around it.
Yarrow Bioscience, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- venBio Global Strategic Fund V, L.P. also filed stake reports on 1 other company: ACHIEVE LIFE SCIENCES, INC. (Apr 2026)
- AI Biotechnology LLC also filed stake reports on 3 other companies: Latigo Biotherapeutics, Inc. (Nov 2026), OnKure Therapeutics, Inc. (Apr 2026), Zura Bio Limited (Mar 2026)
- Bellevue Group AG also filed stake reports on 6 other companies: Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026), Viridian Therapeutics, Inc. (May 2026)
Watch Yarrow Bioscience, Inc.
Get an email when Yarrow Bioscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Yarrow Bioscience, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Yarrow Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Yarrow Bioscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 21 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-28 | Out | President and Chief Executive Officer | 2026-07-27 | 8-K, 2026-07-28 | |
| 2026-07-28 | In | Chief Executive Officer | 8-K, 2026-07-28 |
Who leads Yarrow Bioscience, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Rebecca Frey, appointed (filed 2026-07-28).
- President and Chief Executive Officer: David Domzalski, departure reported, effective 2026-07-27 (filed 2026-07-28). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Yarrow Bioscience, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President and Chief Executive Officer at Yarrow Bioscience, Inc., with the record behind each one.
Find candidates like President and Chief Executive Officer at Yarrow Bioscience, Inc.Every change, in the filing's words
Departing: David Domzalski, President and Chief Executive Officer, effective 2026-07-27
In addition, each of David Domzalski, VYNE's President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE's Chief Scientific Officer, and Mutya Harsch, VYNE's Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026, which terminations are considered to be without "cause" related to a change in control for purposes of their offer letters with VYNE.
Appointed: Rebecca Frey, Chief Executive Officer
On July 27, 2026, the Board appointed Rebecca Frey, Pharm.D. as the Company's Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D. as the Company's Chief Operating Officer, each to serve at the discretion of the Board.
- Resignation of Directors and Certain Officers In accordance with the Merger Agreement, at the Effective Time, all of the Company's directors resigned from the Board and any respective committee of the Board of which they were members.
- The resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.
- The size of the Board was increased to six directors.
- Subject to their execution and non-revocation of a release of claims, each of Mr. Domzalski, Mr. Stuart and Ms. Harsch will be eligible for the separation benefits set forth under their offer letters, as previously disclosed in the Proxy Statement/Prospectus.
- Stock Incentive Plan On April 23, 2026, the Board approved the Yarrow Bioscience, Inc. 2026 Stock Incentive Plan (the "2026 Stock Plan"), subject to stockholder approval and the consummation of the Merger.
- On July 16, 2026, the Company's stockholders approved the 2026 Stock Plan at the Special Meeting and on July 27, 2026, the Board ratified the 2026 Stock Plan.
- The purpose of the 2026 Stock Plan is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of the Company and its stockholders by providing stock-based compensation and other performance-based compensation.
- The initial share pool under the 2026 Stock Plan is 2,688,931.
Tools for this story
Each opens in a new tab, filled in for Yarrow Bioscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.